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Spinal muscular atrophy (SMA) is a severe, inherited disease characterized by the progressive degeneration and 
death of motor neurons of the anterior horns of the spinal cord, which results in muscular atrophy and weakness 
of variable severity. Its early-onset form is invariably fatal in early childhood, while milder forms lead to per- 
manent disability, physical deformities and respiratory complications. Recently, two novel revolutionary 
therapies, antisense oligonucleotides and gene therapy, have been approved, and might prove successful in 
making long-term survival of these patients likely. In this perspective, a deep understanding of the pathogenic 
mechanisms and of their impact on the interactions between motor neurons and other cell types within the 
central nervous system (CNS) is crucial. Studies using SMA animal and cellular models have taught us that the 
survival and functionality of motor neurons is highly dependent on a whole range of other cell types, namely 
glial cells, which are responsible for a variety of different functions, such as neuronal trophic support, synaptic 
remodeling, and immune surveillance. Thus, it emerges that SMA is likely a non-cell autonomous, multifactorial 
disease in which the interaction of different cell types and disease mechanisms leads to motor neurons failure 
and loss. This review will introduce the different glial cell types in the CNS and provide an overview of the role of 
glial cells in motor neuron degeneration in SMA. Furthermore, we will discuss the relevance of these findings so 
far and the potential impact on the success of available therapies and on the development of novel ones. 
 
 
 
 
1. Introduction 
 
Spinal Muscular Atrophy (SMA), also termed 5q-SMA to distinguish 
from less common forms, is a hereditary neuromuscular disease, caused 
by loss-of-function mutations in the gene Survival Motor Neuron 1 
(SMN1), causing the reduction of SMN protein, and characterized by 
hypotonia and weakness, which might prove fatal in early childhood 
(Faravelli et al., 2015; Pearn, 1978; Sumner et al., 2016). SMA has been 
considered for a long time an incurable deadly disease, until recent 
therapeutic advances, namely antisense oligonucleotides and gene 
therapy, have been successful in modifying its natural history from a 
rapidly fatal disease to a condition in which long-term survival is likely 
(Parente and Corti, 2018). At a pathological level, SMA is defined by 
the degeneration of anterior horn cells in the spinal cord and motor 
nuclei in the lower brainstem, which results in a progressive, diffuse 
and symmetric muscle weakness and atrophy (Pearn, 1978). However, 
despite the traditional belief that SMA is a motoneuronal-restricted 
 
disease, recent evidence advocates the involvement of many different 
cells and systems alongside with motor neurons in the pathogenesis of 
this disease. Glial cells are the most abundant cell type in the central 
nervous system (CNS), surrounding neurons and providing nutritional 
and trophic support for them (Papadimitriou et al., 2010). These cells 
also play an important role in neuronal communication and neuroin- 
flammation (Papadimitriou et al., 2010). Although the presence of cell- 
autonomous motoneuronal toxicity in this disease has been established, 
growing evidence supports the possibility that, in addition to that, glial 
dysfunction and glial-mediated inflammation might be able to com- 
promise neuronal survival and promote progression and propagation of 
the degenerative process (Philips and Rothstein, 2014). Arguably, it can 
be hypothesized that, under specific circumstances, neuroinflammatory 
cells - astrocytes and microglia – could directly start the process of 
neurodegeneration. In this review, we will briefly recapitulate the dif- 
ferent glial cell types and their role within the CNS, and we will provide 
an overview of the different mechanisms implicated in glial-mediated 
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neuronal damage. The understanding of these pathways might pave the 
way to the development of therapies specifically targeting glial dys- 
function in SMA. 
 
2. Spinal muscular atrophy 
 
2.1. Clinical and genetic features of 5q-Spinal Muscular Atrophy 
 
Notably, 5q-SMA is the most common cause of child and infant 
mortality  with  a  neuromuscular  etiology  (Brzustowicz  et  al.,  1990; 
D'Amico et al., 2011; Pearn, 1978) It is characterized by the selective 
loss of spinal cord motor neurons (and sometimes also brainstem motor 
nuclei), muscular atrophy and muscular failure (D'Amico et al., 2011). 
In the majority of cases, the genetic culprits are biallelic deletions or 
mutations in the Survival Motor Neuron 1 gene (SMN1) on chromosome 
5 (5q13.2), leading to deficiency of the SMN protein (Frugier et al., 
2002). Among them, the most common mutation (present in almost 
95% of the patient with SMA) is the deletion of exon 7 in SMN1 (Frugier 
et al., 2002). Although its biological roles have not been completely 
elucidated yet, it is known that SMN, in collaboration with partner 
proteins, catalyzes the assembly of snRNPs (which are building blocks 
for pre-mRNA splicing) (Juntas Morales et al., 2017). Moreover, dif- 
ferent  studies  suggest  that  SMN  could  have  also  a  role  in  axonal 
transport and in the formation, maintenance and remodeling of the 
neuromuscular junction (NMJ) (Juntas Morales et al., 2017). 
Differences in SMN protein functioning and in disease phenotypes 
seem to be related, at least in part, to the residual activity of SMN 
protein, which in turn relates to the number of copies of a similar gene 
called SMN2 (Frugier et al., 2002). This gene differs from SMN1 for 1% 
of the sequence, presenting a thiamine in place of a cytosine at codon 
280 in exon 7 (Lorson et al., 1999). This modification determines the 
production of a truncated, non-functional SMN protein from 85 to 90% 
of the SMN2-derived mRNA. The remaining 10–15% of SMN2-derived 
mRNA can instead produce a full-length and functioning SMN protein, 
thus generating a very small amount of functional SMN protein (Lorson 
et  al.,  1999). 
For this reason, the loss of function of SMN1 can be partially com- 
pensated by the SMN2-derived protein synthesis. The number of SMN2 
copies is not constant and varies between different individuals, thus the 
variation in SMN2 copy number partially explains the phenotypic 
variability within SMA patients (D'Amico et al., 2011; Feldkötter et al., 
2002). Indeed, disease  severity is usually inversely  proportional to 
SMN2 gene copy number. Milder phenotypes are associated with the 
presence of 3 or more copies of SMN2. The expression of 8–16 SMN2 
copies, that has been tested in a murine model, completely eliminated 
the pathologic phenotype in mice (Monani et al., 2000). 
While this is the genetic mechanism underlying the most common 
SMA form, there are also different forms of disease lacking SMN1 mu- 
tation, which present marked clinical and genetic heterogeneity. Non- 
5q SMA subtypes are thoroughly reviewed in (Peeters et al., 2014). 
Nonetheless, this review will focus on 5q-SMA, as it is the most common 
and widely studied form and the target of the most recent therapeutic 
innovations. 
5q-SMA is classified in 5 types: 0, 1, 2, 3, and 4, depending on the 
age of onset (prenatal, infantile, adult) and on clinical features (most 
severe, severe, intermediate, mild). Common clinical features are 
symmetric, and predominantly proximal weakness, especially in the 
lower limbs, and absent or markedly reduced deep tendon reflexes 
(DTR) (D'Amico et al., 2011). In some cases (especially in types 0 and 1) 
SMA is correlated with progressive respiratory failure and sleep re- 
spiratory disturbances requiring non-invasive ventilation (NIV) 
(Boentert et al., 2017; Grychtol et al., 2018). 
As mentioned above, SMA is clinically classified in types depending 
on age of onset and disease course. SMA type 0 and type 1 patients can 
display several systemic features, such as autonomic dysfunction, car- 
diac  failure  and  cutaneous  necrosis  (Simone  et  al.,  2016).  These 
characteristics  are  even  more  evident  in  transgenic  mouse  models 
(Shababi et al., 2010). 
The frequency and severity of systemic involvement increases pro- 
portionally to the reduction of SMN protein levels. This relation is 
possibly due to the role of SMN in the RNA metabolism pathways. 
Multi-organ involvement in SMA include a variety of symptoms, 
ranging from vascular and cardiac alterations, to immune system ab- 
normalities and peripheral nerve involvement (Simone et al., 2016). 
Additionally, severe SMA patients may present several cardiac altera- 
tions caused mainly by congenital anomalies that emerge early in car- 
diogenesis. Thus, a current suspect is that SMN may play a key role in 
cardiogenesis. Other symptoms that can be found in patients with SMA 
are hypocalcemia-related osteopenia, pancreatic defects, alterations in 
the fatty acids metabolism and hepatic impairment, and reproductive 
system defects (Abati and Corti, 2018). Systemic symptoms in SMA 
patients have been thoroughly reviewed by Simone and colleagues in 
Simone et al. (2016). 
In the last years, we witnessed a true revolution in the field of SMA 
therapeutics, and of motor neuron diseases in general. In 2016, an 
antisense oligonucleotide called Nusinersen was approved by the Food 
and Drug Administration (FDA) and, subsequently, by the European 
Medical Agency (EMA) for the treatment of SMA (US Food and Drug 
Administration, 2016). Nusinersen works by binding to an intronic 
sequence in exon 7 in SMN2 mRNA, thereby determining skipping of 
exon 7 and production of a full-length, functional protein (Finkel et al., 
2017). Furthermore, in 2019 the FDA approved a second drug, ona- 
semnogene abeparvovec, an adeno-associated virus (AAV)-based gene 
therapy that delivers a functional SMN full-length cDNA to motor 
neurons, for children less than 2 years (Hoy, 2019). Thus, a deep un- 
derstanding of the developmental effects of SMN deficiency in all cell 
types, is necessary in order to fully monitor treated patients and to 
identify the correct timing and delivery methods for these therapies. 
 
2.2. Is SMA a multisystemic disease? 
 
As mentioned above, SMA is a neurodegenerative disease involving 
motor neurons, but many studies suggest that different organs take part 
in its phenotype, especially in the most severe forms, in which the 
depletion of SMN protein is profound. 
The contribute of non-motor neuronal cells to the pathogenesis has 
been demonstrated by the fact that SMN restoration in motor neurons in 
in vivo models is not sufficient to completely restore muscle function- 
ality. Although the restoration of SMN1 in SMA mice under the moto- 
neuronal-specific choline acetyltransferase (ChaT) or homebox 9 (HB9) 
gene proved able to revert synaptic degeneration and reduce muscle 
atrophy (Gogliotti et al., 2012; Lee et al., 2012a; Martinez et al., 2012), 
while muscle-restricted expression could not (Martinez et al., 2012), 
only minimal improvements in motor performance and survival were 
observed. The limited efficacy of neuronal-only, SMN1-enriched trans- 
gene models could be ascribed to failure of these models to address 
disease mechanisms other than neurodegeneration, such as autonomic 
dysfunction that was a prevalent morbidity cause in these mice 
(Gogliotti et al., 2012). Additional evidence of the benefit of SMN1 
restoration not restricted to motor neurons comes from the observation 
that expression of SMN under the prion promoter (PrP), which is highly 
expressed both in neurons and in astrocytes, provokes a dramatic im- 
provement in animal survival (average 210 days) and a normal lumbar 
motor neurons count (Gavrilina et al., 2008). These and other data 
suggest that not only motoneurons, but also astrocytes, sensory neu- 
rons, Schwann cells and myocytes can contribute to the expression of 
the disease and the loss of MNs (Jablonka et al., 2006; Mentis et al., 
2011). 
In addition to that, Hua and collaborators demonstrated that sys- 
temic administration of oligonucleotides that correct SMN2 splicing 
almost completely rescued disease signs, in particular peripheral tissues 
necrosis, in mild SMA mice, and significantly extended survival of 
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severe SMA mice, with noticeable improvements in motor neuron sur- 
vival, neuromuscular junction integrity, and motor function; this effects 
were not achieved with intracerebroventricular (ICV) administration 
(Hua et al., 2011). Accordingly, they conclude that the SMA phenotype 
in murine models is not the result of a selective motor neuron defect 
alone. 
 
2.3. Involvement of non-motor neuronal neural cells in central and 
peripheral nervous system 
 
As we mentioned, several lines of evidence seem to suggest that non 
only motor neurons, but also other cell types may be affected by SMN1 
depletion. Notably, in milder SMA forms with higher levels of SMN non- 
motor neuronal and systemic symptoms are less evident, while severe 
forms show a higher percentage of these complications (Shababi et al., 
2010; Simone et al., 2016). Therefore, it could be hypothesized that 
there is a variable susceptibility threshold for SMN reduction in dif- 
ferent types of cells (Simone et al., 2016). 
For instance, early dysfunction of sensory neurons and disruption of 
sensory-motor circuits has been widely demonstrated in preclinical 
studies (Imlach et al., 2012; Jablonka et al., 2006; Lotti et al., 2012; 
Mentis et al., 2011). Indeed, abnormal conduction velocity and sensory 
neuronopathy with neurogenic changes at muscle biopsy are very 
common in SMA-1 patients (Anagnostou et al., 2005; Omran et al., 
1998; Rudnik-Schöneborn et al., 2003). A recent study has revealed 
that motor neuron degeneration follows a dysregulation of mRNAs 
which are necessary for the formation of synaptic connections between 
sensory and motor circuitries in SMA mice spinal cord (Zhang et al., 
2013). Indeed, deep RNA sequencing on human SMA motor neurons 
derived from patients human induced pluripotent stem cells (iPSC) 
revealed specific altered gene splicing/expression. Many deregulated 
genes, such as the neurexin and synaptotagmin families, are implicated 
in critical motor neuron functions (Rizzo et al., 2019) 
Moreover, it was shown that the first symptomatic stages in SMA are 
characterized by morphological and functional abnormalities of neu- 
romuscular synapses (Dachs et al., 2013; Kariya et al., 2008; Kong et al., 
2009; Lee et al., 2011). 
In addition to that, patients with SMA suffer from esophageal reflux, 
constipation and delayed gastric emptying, which might be a direct 
consequence of SMN deficiency in neurons of the enteric nervous 
system (ENS), rather than a secondary event. In murine models, SMN 
deficiency in the ENS resulted in constipation, delayed gastric emp- 
tying, slowing of intestinal transit and reduced motility of the colon 
(Gombash et al., 2015). In particular, SMN deficiency causes interrup- 
tion of ENS signaling to colon smooth muscle. Defects in cardiac au- 
tonomic innervation, with reduced sympathetic neuron staining and 
axon branches, were also observed in SMA mice (Gogliotti et al., 2012; 
Heier et al., 2010). 
 
3. Motor neurons involvement in SMA 
 
Traditionally, the main anatomopathological manifestation of SMA 
was the motor neurons degeneration within the anterior horn of the 
spinal cord. The same degenerated neurons, rich in phosphorylated 
neurofilaments, have also been found at the level of the thalamus, of the 
dorsal root ganglia and of the motor nuclei of the extrinsic ocular 
musculature (D'Amico et al., 2011). 
Although SMN protein influences the RNA processing functions in 
all cells, it explicates its prominent role and pathogenic effect in mo- 
toneurons through mechanisms that are still not completely under- 
stood. 
As mentioned above, SMN contributes to the formation of snRNPs, 
and thus loss of SMN protein determines aberrant splicing and wide- 
spread transcriptional changes to which motor neurons are especially 
vulnerable (Bäumer et al., 2009; Corti et al., 2012;  Ng et al., 2015; 
Rizzo et al., 2019). Furthermore, SMN regulates mRNA translation and 
trafficking of RNA-binding proteins in neurites as well, thus impairing 
normal neurite function and extension in in vitro SMA models (Fallini 
et al., 2014, 2011; Jablonka et al., 2007; Rossoll et al., 2003) Recently, 
SMN was shown to be implicated in the biogenesis of microRNAs 
(miRNAs), which could also explain the numerous pathways that are 
affected by SMN loss (Magri et al., 2018). Thereby, its deficiency could 
result in the alteration of the expression of motor neuron-specific se- 
lected miRNAs. 
In addition to RNA metabolism dysregulation, several studies have 
shown the presence of an assembling defect of neurofilaments in af- 
fected motor neurons, and have advanced the hypothesis that this de- 
fect could influence the formation of synapses and disturb the neuron- 
glia relationship (Chou and Nonaka, 1978). A reduced positive response 
to synaptophysin in these motor neurons has been reported, confirming 
the loss of synapses. 
Novel murine models expressing a reduction of the SMN protein 
specifically in the motoneuronal progenitors were developed in order to 
test the effects of a motoneuronal-specific SMN reduction (Park et al., 
2010a). To this aim, Park and colleagues performed a selective deple- 
tion of the SMN protein in spinal motor neuron progenitors expressing 
the transcriptional repressor Olig2 (Olig2-Cre transgenic mice) (Park 
et al., 2010b). In this study the simple exhaustion of the SMN protein in 
spinal motor neuron progenitor cells was shown to be sufficient to cause 
many of the morphological, functional and phenotypic characteristics 
of human SMA. Progressive silencing caused not only early distal de- 
fects of the NMJ, but also impairment of central synapses and degen- 
eration of the motor neurons with consequent muscular atrophy, sug- 
gesting that the pathology of the motoneurons in SMA is, at least in 
part, a cell-autonomous effect of SMN insufficiency. As well as affecting 
peripheral neuromuscular synapses, the depletion of motoneuronal 
SMN severely impairs central synaptic integrity. 
However, despite the presence of a clear SMA-like pathologic phe- 
notype in these mouse lines, the disease was not as severe as in lines 
with a ubiquitous SMN depletion. Intriguingly, Olig2-Cre mice did not 
progress inexorably to death like their SMN-lacking counterparts, but 
after acquiring motor phenotype they reached a steady state. One po- 
tential explanation for this finding is the role of non-nervous CNS cells 
in sustaining and spreading initial motoneuronal pathology. Supporting 
this hypothesis, previous data have shown that isolated motor neurons 
from SMA mice spinal cord do not die when cultured alone, although 
they die in vivo (Rossoll et al., 2003). Moreover, increasing evidence 
suggests that although the expression of SMN in MNs is essential, its 
recovery is not  sufficient to  significantly improve survival  in SMA 
mouse models. When SMN is highly expressed in both astrocytes and 
MNs, survival is maximized (Lee et al., 2012a; McGivern et al., 2013). 
These data tell us that astrocytes play an important role in the patho- 
genesis of SMA, and that they could represent an additional target for 
therapeutic intervention. 
 
4. Basis of glial cells biology 
 
At the beginning of the XX century, when it was first identified, glia 
was simply considered as “nerve glue” (Jäkel and Dimou, 2017). In the 
subsequent decades, however, it became clear that glia is actually much 
more than that, and that glial cells form a heterogeneous group, with 
various functions and properties which have not been completely un- 
derstood yet (Jäkel and Dimou, 2017). As mentioned above, glial cells 
represent the most abundant cell type within the CNS, forming between 
33% and 66% of the total brain mass (Jäkel and Dimou, 2017). Their 
main functions are to provide structural and trophic support to neurons, 
and to speed nervous conduction by forming myelin coat around axons. 
Nonetheless, glial cells exert also a variety of additional, less-known 
activities, such as antimicrobial filtering and guidance to synapse for- 
mation. However, the most complex and elusive of glial-dependent 
functions is perhaps neuroinflammation. The term “neuroinflamma- 
tion” encompasses a wide range of molecular and cellular processes, 
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happening within the CNS, that result in the activation of glial cells and 
in the infiltration of the nervous tissue by immune cells, and that are 
present in a variety of pathological conditions, including SMA 
(Papadimitriou et al., 2010). 
Glial population can be divided in 4 groups: microglia, astrocytes, 
oligodendrocytes and NG2-glia (progenitors of the other subgroups). 
Astrocytes, oligodendrocytes and NG-2 progenitors originate from ec- 
todermal tissue, whereas microglia derives from the yolk sac (Jäkel and 
Dimou, 2017). Microglial cells are the main immune-competent cells in 
the CNS and are deputed to immune surveillance. Microglial cells 
produce a whole range of pro-inflammatory and anti-inflammatory 
mediators (cytokines and chemokines) and eliminate not only foreign 
microorganisms but also compromised cells. After an injury, they are 
massively activated in the regions of neural loss, determining a condi- 
tion known as “reactive microgliosis”, and working in close interaction 
with inflammatory T-lymphocytes as well as astrocytes in order to 
provide inflammatory response (Moisse and Strong, 2006). Microglia 
can secrete both pro- and anti-inflammatory cytokines and chemokines 
in different combinations, depending on the received stimuli deriving 
from surrounding microenvironment and/or from other cells, and thus 
they can acquire a different phenotype according to these variables 
(“pro-inflammatory” or M1 versus “anti-inflammatory” or M2 pheno- 
type) (Tang and Le, 2016). New evidence suggests that these cells also 
have an essential role in homeostasis, neuronal survival and synaptic 
pruning (Cowan and Petri, 2018). 
Astrocytes have emerged as critical elements for the maintenance 
and function of the CNS: they maintain neural functioning, control 
neural maturation and differentiation and transfer nourishment from 
the blood stream to neurons through a capillary gap-junctions system 
(Vasile et al., 2017). Healthy astrocytes greatly participate in the reg- 
ulation of synaptic function, providing an optimal pre-synaptic en- 
vironment, triggering synaptic maturation and pruning, maintaining 
synaptic activity and stability (Pehar et al., 2005; Vasile et al., 2017). 
For instance, they participate in the glutamate-glutamine circle, taking 
up glutamate from the synaptic cleft after release from presynaptic 
terminal, thus preventing excessive postsynaptic stimulation of gluta- 
mate receptor which eventually leads to cell death, the so-called “glu- 
tamate-mediated  excitotoxicity”  (Danbolt,  2001).  They  are  also  key 
components of the blood brain barrier (BBB) and may regulate blood 
flow in the brain trough vasoconstriction and vasodilation (Farina et al., 
2007). In addition to that, astrocytes are able to improve neural sur- 
vival and control neural differentiation and growth by releasing dif- 
ferent neurotrophic factors, such as Neurotrofin-3 (NT3) and Brain 
Derived Neurotrophic Factor (BDNF) (Ojeda et al., 2003; Rudge et al., 
1992). Similarly to microglia, astrocytic functions are deeply regulated 
by immune T-cells, surrounding neurons and possibly oligodendrocytes. 
After receiving pro-inflammatory stimuli from a nearby biological ha- 
zard or from other cells, astrocytes react by increasing the expression of 
some astrocytic markers, e.g. glial fibrillary acidic protein (GFAP) and 
aldehyde dehydrogenase 1 L1 (ALDH1L1), and by proliferating in a 
process called astrogliosis (Rothstein et al., 1992; Tawfik et al., 2008). 
Oligodendrocytes are glial cells abundantly present within the CNS. 
Mature oligodendrocytes produce myelin, a specialized structure which 
encloses axons, thus playing a key role in the efficiency and speed of 
impulse conduction (Emery, 2010). There is also compelling evidence 
that oligodendrocytes provide trophic support to neurons, for example 
through the release of GDNF or by transporter-mediated delivery of 
metabolic substrates, such as lactate (Lee et al., 2012b; Ubhi et al., 
2010). Interestingly, myelination occurs late in neural development and 
over a prolonged time frame, lasting for the first two decades of life in 
humans (Mitew et al., 2014). Moreover, it has been shown that myelin 
remodeling and repair continues throughout life (Young et al., 2013). 
Oligodendrocytes arise from oligodendrocyte precursor cells (OPCs), 
which are produced in sequential waves from specific germinal regions. 
OPCs in turn derive from neural progenitor cells (NPCs) of the germinal 
layer (Emery, 2010). 
At last, the main glial cells of the peripheral nervous system are 
Schwann cells, which are essential to axon stability and neuronal sur- 
vival. They release proteins involved in the formation and maintenance 
of the extracellular matrix (ECM) and form the protective myelin sheath 
wrapping around axons of peripheral neurons (Chernousov et al., 
2008). 
 
5. Role of glial cells in neurodegenerative disorders 
 
In the healthy brain, glial cells remain in a state of quiescence. 
When the brain is injured, this cells rapidly activate in response to 
specific molecular signals, developing neuroinflammation (DiSabato 
et  al.,  2016). 
Neuroinflammation is an innate immune response that occurs 
within the CNS against harmful stimuli such as pathogens, metabolic 
toxic waste or chronic stress that occurs in response to trauma, infec- 
tions and/or neurodegenerative disease (DiSabato et al., 2016). The 
main cell types contributing to this immune response are microglia and 
astrocytes. These cells constantly survey the environment through 
pattern recognition receptors (PRRs). After activation of the PRRs and 
release of immune molecules, the innate immune system launches in- 
flammatory and regulatory responses in order to counteract infection, 
injury and maintenance of tissue homeostasis (DiSabato et al., 2016). 
An example of the beneficial effects of neuroinflammation is that re- 
active microglia can enhance neuronal repair through “synaptic strip- 
ping”, a form of controlled-phagocytosis in which it removes pre-sy- 
naptic axon terminals from damaged neurons with the aim of directing 
cell efforts towards repair rather than information processing, both in 
healthy and diseased brain (Moisse and Strong, 2006). In Amyotrophic 
Lateral Sclerosis (ALS), this mechanism was shown to occur as an early 
phenomenon and with ongoing synaptic loss through disease progres- 
sion, in response to cell injury (Kassa et al., 2018; Zang et al., 2005). In 
addition, it was shown that, after injection of kainic acid, an excitotoxic 
damage-inducer, into the striatum of healthy mice, reactive astrocytes 
could produce high amounts of nerve growth factor (NGF) and lead to 
the formation of a glial scar, which acts as a physical barrier around the 
injured area and as a permissive substratum for axonal regeneration 
(Strauss et al., 1994). Indeed, elevated levels of NGF were observed in 
brains of patients with Alzheimer's Disease (AD) (Crutcher et al., 1993; 
Hock et al., 2000). Finally, both microglia and astrocytes play an im- 
portant role in neuroprotection, as they can preserve neuronal survival 
through the release of cytokines, neurotrophins and anti-inflammatory 
growth factors (Zhao et al., 2004). Beneficial effects of stem cell grafts 
giving rise to growth factor-releasing glial lineages was demonstrated in 
several ALS mouse models (Abati et al., 2019). Although the evolu- 
tionary function of this mechanism is protective, innate immune re- 
sponses of neuroinflammation can also promote neural damage when 
excessive or unproportionate. Chronic neuroinflammation is observed 
at relatively early stages of ALS, AD and other neurodegenerative dis- 
eases (Eikelenboom et al., 2002; Heneka et al., 2014; Sargsyan et al., 
2005). During chronic activation, the sustained exposure of neurons to 
pro-inflammatory mediators can cause neuronal dysfunction and con- 
tribute to cell death. Activated glial cells can produce toxic molecules 
(such as ROS and NO) which mediate a noxious action on neighboring 
neurons (MacMicking et al., 1997). 
Each glial cell subtype exerts a different role within the CNS. As 
mentioned above, microglia represents the first line of CNS im- 
munological defenses. After a lesion, in response to molecular signals 
(interferon γ, tumor necrosis factor α, macrophage colony stimulating 
factor, and granulocyte macrophage colony stimulating factor), mi- 
croglial cells change morphology, passing from a branched phenotype 
to an early activated phenotype, or “primed” state, up to an actual 
active amoeboid phagocytic phenotype (Kreutzberg, 1996). 
Astrocytes are not professional immune cells, but when activated 
can contribute to the local immune response. Once triggered after a 
brain injury, they become reactive and respond to pro-inflammatory 
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Fig. 1. The figure illustrates the pathogenic processes underlying SMA pathology in the CNS. Communication between astrocytes and neurons is impaired because of 
defect in ATP and calcium-mediated signaling. Similarly, structural dysfunction of astrocytes leads to decreased trophic support to motor neurons. An increase in the 
presence of activated M1 microglia is observed, with production of pro-inflammatory cytokines and activation of apoptotic cascade. Furthermore, activated microglia 
in SMA was shown to contribute to synapse loss through a process called synaptic stripping. The formation of a neurotoxic milieu causes the infiltration of immune 
cells which further reinforce microglial activation and neuroinflammation. 
 
cytokines by proliferating and changing their morphology, growing 
numerous processes and developing hypertrophic nuclei (Pehar et al., 
2005). Healthy astrocytes activated by peroxynitrite administration in 
vitro are able to promote apoptosis in previously healthy neighboring 
MNs through the release of ROS which in turn compromise the integrity 
of neighboring cells by damaging cell membrane proteins and lipids, as 
well as by oxidizing essential proteins for the MNs survival (Cassina 
et  al.,  2002). 
From these studies, two main hypotheses for the sequence of events 
in glial response have emerged: a simultaneous activation hypothesis 
and a sequential activation one (Papadimitriou et al., 2010). The first 
hypothesis suggests that astrocytes and microglia react in concert to 
similar pathological signals that derive, for example, from compro- 
mised neighboring neurons. Conversely, the second hypothesis ad- 
vocates that microglia and astrocytes could be able to influence each 
other: the activation of the microglia would determine increase of cy- 
tokines and NO, which can modulate astrocyte activation, and at the 
same time activated astrocytes would release cytokine and chemokines 
that activate microglia (Moisse and Strong, 2006; von Bernhardi and 
Eugenín,  2004). 
Oligodendrocytes dysfunction has also been recognized in several 
neurodegenerative diseases, such as Parkinson's disease (PD) and 
Multiple System Atrophy. Indeed, close interconnection between oli- 
godendrocytes and neurons is further proved by the fact that mice 
lacking the expression of specific oligodendrocyte markers develop 
axonal degeneration independent of demyelination (Griffiths et al., 
1998; Lappe-Siefke et al., 2003). Among the hypothesized mechanisms, 
oligodendrocytes' dysfunction might cause neuronal death through the 
activation of neuroinflammatory mechanisms and the loss of neuro- 
trophic support (Brudek et al., 2013; Fellner et al., 2013; Li et al., 2018; 
Ubhi et al., 2010; Zhang et al., 2005) 
It remains to be clarified which signals trigger glial activation and 
which is the sequence in which the different inflammatory cells and 
mediators are recruited into play. To date, a convincing demonstration 
of such cell-cell interactions is still lacking, as contrasting data have 
been generated using different animal models. 
 
6. Glial cells involvement and neuroinflammation in SMA 
 
Some groups have shown that the loss of MN is detectable only in 
the final phase of the SMA (Kong et al., 2009; Ling et al., 2010). Before 
the loss of MNs, pre-synaptic defects appear, which include the loss of 
terminal arborization and the aggregation of intermediate filaments, 
which causes intermittent failures in neurotransmission (Kariya et al., 
2008). Therefore, it can be deduced that the death of motoneurons is a 
late event in the pathogenesis of SMA, preceded by the activation of 
glial cells that could sustain and spread the degenerating process (Wang 
and Bordey, 2008). Indeed, in all types of human SMA, gliosis was re- 
ported to be associated with areas of motor neurons degeneration in the 
spinal cord and brain stem (Araki et al., 2003; Kuru et al., 2009). An 
important pathological feature of this disease is the glial bundle for- 
mation, especially in anterior roots and in the lumbar regions of the 
spinal cord, where motor neuron loss and glial activation are found 
(Ghatak, 1983). These bundles are thought to represent a protrusion of 
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reactive astrocytes into the neurilemmal tubes containing degenerating 
myelinated axons. In type II SMA, it was shown that gliosis in the spinal 
cord and in the brainstem is associated with a severe reduction of MN 
number, and that oxidative stress-related products are deposited into 
the remaining atrophic MNs (Araki et al., 2003). 
As explained before, astrocytes and microglia activate in response to 
inflammatory stimuli and promote neuroinflammation, resulting in 
cytokines production, immune infiltration and activation of pro-apop- 
totic pathways. Traditionally, neuroinflammation was believed to be a 
secondary event, subsequent to neuron loss, and aimed at limiting 
cellular damages and at promoting CNS regeneration. However, as 
discussed below, this concept has been challenged by recent studies. 
Thus, glial cells dysfunction is believed to promote the pathogenesis 
of SMA in several ways, which we are now going to illustrate (Fig. 1). 
 
6.1. Astrocytic dysfunction and defective astrocyte-neuron interaction 
 
Several findings support a contribution of astrocytes to SMA de- 
velopment. For instance prominent astrogliosis can be found at the level 
of the spinal cords in post-mortem SMA-1 patients, with an increase in 
GFAP-staining cells and in IL-6 and IL-1beta (Rindt et al., 2015). 
SMN deficiency has been shown to impair normal astrocytic func- 
tion in several ways (Table 1). Indeed, it has been observed that, during 
disease progression, astrocytes become reactive exhibiting both mor- 
phological and functional changes, and these activation-related mor- 
phological alterations appear long before the loss of the motor neurons 
(McGivern et al., 2013). McGivern and colleagues have recently shown 
that, starting from postnatal day 9, astrocytes in the spinal cord of a 
transgenic SMA murine model display an enlargement of cellular 
bodies, increased expression of GFAP in the cytoplasm and retracted 
processes (McGivern et al., 2013). These alterations were retrieved in 
induced pluripotent stem cell-derived SMA astrocytes as well. Both 
these findings seem to highlight that astrocytic dysfunction and loss in 
SMA might be a direct consequence of SMN deficiency, rather than of a 
diseased microenvironment. In the same study, a dysregulation of basal 
calcium and a reduction in the response to ATP stimulation were ap- 
preciated, thus suggesting a dysfunction of ATP and calcium-mediated 
transmission between astrocytes and neurons (McGivern et al., 2013; 
Parpura and Zorec, 2010). Another proof of a defective astrocyte-motor 
neuron communication comes from the observation that, in moto- 
neuron–astrocyte contact cocultures, synapse formation and synaptic 
transmission were significantly reduced when either motoneurons, as- 
trocytes or both were from SMA mice compared with wild-type co- 
cultures (Zhou et al., 2016). Additionally, a downregulation of Ephrin 
B2, a membrane-binding ligand which regulates synapse formation, was 
retrieved in SMA astrocytes, thus suggesting a possible mechanisms 
linking astrocytes, motor neurons and the observed synaptic dysfunc- 
tion. Moreover, astrocytes in SMA have been shown to contribute to 
motor neuron dysfunction also by decreased production of supportive 
factors such as monocyte chemoactive protein 1 (MCP1), a chemokine 
linked to neuroprotection from excitotoxicity, in cellular cultures 
(Martin et al., 2017). Its restoration reverted negative effects on motor 
neurons' bodies and neurites, thus correction of MCP1 deficiency early 
in the disease has been proposed by authors as a potential therapeutic 
approach to SMA. However, as MCP1 is also implicated in inflammatory 
process, its effects are not completely clear. 
We have discussed above the potential role of motoneuronal-spe- 
cific miRNAs alterations in SMA-related motoneuronal damage. 
Stemming from these observations, Sison and colleagues detected the 
upregulation of miR-146a in the secretome of SMA astrocytes (Sison 
et al., 2017). miR-146a is involved in modulating the immune system in 
response to interleukins and TNFα production. Furthermore, motor 
neurons loss induced by SMA astrocyte conditioned medium (ACM) is 
reverted by a miR-146a inhibitor. Potential downstream targets of miR- 
146a include downregulation of GDNF and GATA transcription factors, 
which are required for organogenesis. 
The timing of astrocytic dysfunction and its temporal relationship to 
motoneuronal damage remain a matter of debate, although recent 
studies have challenged the traditional belief that it was a secondary 
event. It was observed that in both in vitro and in vivo SMA models there 
 
Table 1 
Studies regarding astrocytes' dysfunction in in vivo and in vitro SMA models. 
 
 
Model Relevant results Ref 
 
SMA iPSC-derived astrocytes and SMNΔ7-tg-mice spinal cord sections - SMA astrocytes show signs of activation by characteristic morphological 
changes and up-regulation of GFAP and Nestin 
- Dysregulation of basal calcium and reduced response to ATP stimulation 
- Increased phospho-ERK1/2 expression and reduced GDNF production 
 
McGivern et al., 
2013 
SMNΔ7-tg-mice treated with scAAV9-SMN(gfap); human SMA spinal 
cord  sections. 
 
 
 
 
 
Spinal cord astrocytes and motoneurons primary cultures and 
cocultures from WT and SMNΔ7-tg-mice 
 
 
 
Astrocytes and motoneurons cultures from spinal cord of WT and 
SMNΔ7-tg-mice and from control and SMA patients iPSCs 
 
Astrocytes and motor neurons cultures from control and SMA 
patients-derived iPSCs 
 
 
 
 
SMNΔ7-tg-mice spinal cord sections and SMA iPSCs-derived 
astrocytes 
- Astrogliosis was prominent in end-stage SMA mice and in post-mortem patient 
spinal cords 
- Restoring SMN in astrocytes improves lifespan and gross motor function and 
rescued defects in NMJs and proprioceptive synapses 
- Increased expression of proinflammatory cytokines was partially normalized 
in treated mice 
- SMN deficiency in MNs impairs synapse formation and function 
- SMN deficiency in astrocytes alters calcium concentrations 
- SMN deficiency alters motoneuron–astrocyte interactions in synapse 
formation and function in contact cocultures 
- SMN deficiency alters Ephrin B2 expression in astrocytes 
- SMA mice ACM provides decreased support of isolated MNs 
- SMA astrocytes produce decreased amounts of MCP1, and its supplementation 
improves motoneuronal growth 
- increased production and secretion of miR-146a as compared to control in 
SMA astrocytes 
- Treating MNs with synthesized miR-146a molecules induces significant MNs 
loss 
- MNs loss induced by SMA ACM is blocked by a miR-146a inhibitor. 
- Downregulation of GDNF and GATA transcription factors 
- Dysregulation of Notch signaling in the spinal cord in both early and late 
stages of SMA 
- Pharmacological inhibition of Notch signaling improved the motor functional 
deficits in SMA model mice 
Rindt et al., 2015 
 
 
 
 
 
 
Zhou et al., 2016 
 
 
 
 
 
Martin et al., 2017 
 
 
Sison et al., 2017 
 
 
 
 
 
 
Ohuchi et al., 2019b 
 
 
Abbreviations: ACM, astrocyte-conditioned medium; GDNF, glial derived neurotrophic factor; iPSC, induced pluripotent stem cell; MN, motor neuron; NMJ, neu- 
romuscular junction; SMA, spinal muscular atrophy;SMN, survival motor neuron; tg, transgenic; WT, wild-type. 
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was an alteration of Notch signaling, a mechanism of juxtacrine com- 
munication between adjacent cells that promotes astrogenesis and as- 
trocytic differentiation (Caraballo-Miralles et al., 2013; Ohuchi et al., 
2019b). These findings suggest that chronic SMN depletion during de- 
velopmental stages might act via Notch signaling dysregulation causing 
an abnormal increase in astrocytes in early stages. Furthermore, acti- 
vation of astrocytes in SMA models seems to appear before motor 
neuron loss, as early as postnatal day 0–1, thus suggesting it could be a 
primary event in SMA pathogenesis (Dachs et al., 2011; McGivern et al., 
2013). 
Selective restoration of SMN protein levels in astrocytes by viral 
vectors was attempted by Rindt and colleagues, who found that it re- 
sulted in increased survival in intermediate and severe SMA models and 
in a partial normalization of the production of pro-inflammatory cyto- 
kines (Rindt et al., 2015). Notably, SMN restoration did not cause an 
increase in motor neuron numbers, but rather in the rescue of defects of 
neuromuscular junctions and proprioceptive synapses, suggesting that 
the observed treatment effects likely protected and functionally en- 
hanced the remaining motor neurons. 
 
6.2. Microglial involvement and synaptic remodeling in SMA 
 
Not only astrocytes, but also microglia seem to be involved in SMA 
pathogenesis (Table 2). Recently, Tarabal and colleagues confirmed the 
presence of activated microglia in the lumbar enlargement at different 
disease stages in a rodent SMA model (Tarabal et al., 2014). In this 
model, the immunoreactivity for the specific microglial marker (Iba1) is 
significantly increased starting from the early symptomatic stages, 
surrounding the ventral horn motor neurons, thus suggesting the pre- 
sence of active neuroinflammation. 
In addition to that, they detected active microglial cells containing 
swallowed structural complexes, such as damaged presynaptic term- 
inals and post-synaptic dendrites. The phagocytic function of microglia 
is an increasingly recognized phenomenon in many neurodegenerative 
diseases, and these results seem to underline the importance of the 
action of this type of cells in the elimination of cellular fragments 
during the degeneration of a synapse (Fu et al., 2014). These results 
confirm similar findings of a previous work by Ling and colleagues, 
which observed an increased colocalization of activated microglia with 
intense Iba1 immunoreactivity and MNs in the spinal cord, alongside 
with a reduction in central synapses, particularly glutamatergic ones, at 
the level of MNs (Ling et al., 2010). All these observations are in line 
with the hypothesis that microglia might contribute to synapse loss 
through  a  process  called  synaptic  stripping,  in  which  microglia, 
following insults in both central and peripheral nervous system, phy- 
sically removes synaptic inputs from motor neurons (Perry and 
O'Connor, 2010). 
A subsequent study further investigated activation of microglia in a 
murine SMA model, revealing that affected mice presented, in addition 
to microgliosis, a dramatic increase in harmful M1 microglia (Mac-2+) 
and a significant reduction in beneficial M2 cells (CD206+) in  the 
spinal cord. Treatment with PRE-084, a sigma-1-receptor (Sig1R) acti- 
vator, reduced the density of immunoreactive profiles and enhanced the 
number of CD206-immunolabeled cells found in murine spinal cord, 
although it was not able to prevent motor neurons loss nor to increase 
survival (Mancuso et al., 2012). This suggests a potential therapeutic 
effect of the activation of Sig1R, a transmembrane protein which seems 
to be implicated in in the protection of cells from both oxidative and 
endoplasmic reticulum-mediated cellular stress, in the reversal of M1/ 
M2 balance disruption found in SMA. 
Another recent study identified in the classical complement system 
the signal that initiate microglia-dependent circuits remodeling 
(Vukojicic et al., 2019). Authors found that C1q and C3, locally pro- 
duced by microglial cells, tag vulnerable synapses in SMA which are 
later removed by microglia, and that SMN deficiency drives C1q tag- 
ging of proprioceptive synapses in the spinal cord. Postnatal block of 
C1q tagging with a monoclonal anti-Cq1 antibody was shown to result 
in synaptic and behavioral benefit in SMA mice. Furthermore, genetic 
deletion of C1q rescued synaptic deficit in SMN-deficient animals. This 
remarkable finding paves the way for further trials of complement in- 
hibition in SMA models, and, perhaps, patients. 
 
6.3. Downstream effects on pro-apoptotic/inflammatory pathways 
 
Reactive astrocytes in SMA are able to trigger downstream in- 
flammation and neuronal damage through the secretion of pro-in- 
flammatory cytokines that can activate the apoptotic cascade. ERK 1–2, 
are members of the MAPK signaling pathway, with both a pro-survival 
and a pro-apoptotic action (Jo et al., 2005). One study showed that 
astrocytes derived from SMA IPSCs have an increased ERK1/2 phos- 
phorylation, which could be a signal for activation of the apoptotic 
pathway through greater expression of pro-inflammatory and pro- 
apoptotic cytokines such as TNFα, IL-1 and IL-6 (McGivern et al., 
2013). However, increased cellular death was not observed, nor it was 
increased secretion of TNFα, thus further studies using more sensitive 
detection methods are needed. 
In addition to that, some of the deleterious effects linked to the glial 
reaction might depend on the activation of the apoptotic machinery 
 
Table 2 
Studies regarding microglial dysfunction in in vivo and in vitro SMA models. 
 
 
Model Relevant results Ref 
 
WT and SMNΔ7-tg-mice spinal cord sections - Loss of central synapses with selective reduction of glutamatergic synapses onto L3–5 lateral 
spinal motoneurons 
- Reduction of proprioceptive sensory neurons 
- Increased association of MNs and microglia in the spinal cord 
WT and SMNΔ7-tg-mice spinal cord sections - Progressive MN size reduction and loss in the spinal cord of affected mice 
- Degenerating MNs show ultrastructural signs of degeneration (mitochondrial vacuolization, 
abnormal nuclei, dendritic degeneration) and mitochondrial depletion 
- Astroglial and microglial activation in ventral horns 
- defects in glutamatergic and GABAergic synaptic afferents 
WT and SMNΔ7-tg-mice spinal cord sections - Progressive astrogliosis and microgliosis around MNs 
- Increase of M1 microglia 
- Treatment with PRE-084 did not prevent MN loss but mitigated astrogliosis and microglia and 
induced M2 microglial phenotype 
 
Ling et al., 2010 
 
 
 
Tarabal et al., 2014 
 
 
 
 
 
Cerverò et al., 2018 
WT mice, SMNΔ7-tg-mice, C1q− -tg-mice and 
SMNΔ7/C1q−   -tg-mice 
- C1q and C3 tag vulnerable synapses in SMA mice, and microglia is responsible for synaptic 
removal 
- SMN deficiency drives C1q tagging of proprioceptive synapses 
- Block of C1q determines synaptic and behavioral improvement 
- Genetic deletion of C1q rescues proprioceptive synapses in SMA mice 
Vukojicic et al., 2019 
 
 
Abbreviations: MN, motor neuron; SMA, spinal muscular atrophy; SMN, survival motor neuron; tg, transgenic; WT, wild-type. 
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Table 3 
Studies regarding Schwann cells' dysfunction in SMA models. 
 
 
Model Relevant results Ref 
 
WT and SMNΔ7-tg-mice - capacity for synaptic sprouting following paralysis was reduced 
- rate of axon growth during nerve regeneration was unchanged 
- nerve-directed reorganisation of acetyl choline receptors was decreased 
- loss of terminal Schwann cells from the neuromuscular junction was observed 
Schwann cells isolated from SMA mouse peripheral nerve - widespread changes to the Schwann cell proteome, in particular regarding 
ubiquitination pathway 
- Pharmacological suppression of Uba1 in Schwann cells was sufficient to 
reproduce the defective myelination phenotype seen in SMA 
 
Murray et al., 2013 
 
 
 
Aghamaleky Sarvestany 
et  al.,  2014 
Schwann cells primary cultures from WT and SMNΔ7-tg-mice 
and cocultures with purified DRG motor neuron from WT 
animals; 
Sections of intercostal and sciatic nerves from WT and 
SMNΔ7-tg-mice. 
- Abnormal myelination of peripheral nerves in SMA mice 
- SMA-derived Schwann cells fail to respond normally to myelination cues 
- Increased apoptosis activation (cas-3) 
- Increased neuronal instability (reduced neurites density) 
Hunter et al., 2014 
WT and SMNΔ7-tg-mice treated with pMpz-SMN1 transgene - Restoration of SMN protein levels restricted solely to Schwann cells reversed 
myelination defects, significantly improved neuromuscular function and 
ameliorated neuromuscular junction pathology in SMA mice. 
- restoration of SMN in Schwann cells had no impact on motor neuron loss 
WT and SMNΔ7-tg-mice - NMJs of the diaphragm of SMA mice show a loss of synaptic vesicles and active 
zones 
- depletion of s100-positive perisynaptic Schwann cells 
Hunter et al., 2016 
 
 
 
Neve et al., 2016 
 
 
 
mediated by pro-inflammatory cytokines IL-6 and IL-8. Cardiotrophin-1 
(CT-1) is a cytokine of the IL-6 family, which has been shown to delay 
axonal motor degeneration in mice with SOD1 overexpression (Bordet 
et al., 1999). The administration of CT-1-expressing adenoviral vectors 
in mouse model with neuron-restricted deletion of exon 7 resulted in an 
increase in survival and in an improvement of motor performances of 
the treated mice (Lesbordes et al., 2003). These results might therefore 
suggest that some cytokines could delay the characteristic degeneration 
in SMA. 
Moreover, further studies have focused on the neuronal apoptosis 
inhibitory protein gene (NAIP), which localizes in the region adjacent 
to SMN1 and is frequently deleted together with SMN1 in 50% of SMA- 
1 cases and in 10–20% of SMA-2 and -3 cases, with a strong correlation 
between the deletion of NAIP and the severity of the disease (Roy et al., 
1995). Furthermore, NAIP is also capable of interacting with TNF-α 
receptor-binding proteins (e.g. TRAF-1 and TRAF-2), blocking cell 
death, and its overexpression was shown to prevent cell death induced 
by NGF withdrawal or TNF-α receptor activation in neuronal precursors 
in vitro (Götz et al., 2000; Rothe et al., 1996). 
TNF-α pathway  is  known  to  contribute  to  neuroinflammation 
through  a  number  of  different  mechanisms  (including  regulating 
apoptosis). In SMA there seems to be an inverse relationship between 
the severity of the disease and the activation of the TNF-α pathway 
(Papadimitriou et  al.,  2010). In particular,  in SMA-1,  an important 
downregulation  of  P38  kinases,  MAP  kinase  interacting  serine  / 
threonine kinase (MNK2) and IL-32 (a pro-inflammatory cytokine), 
which are induced in the TNF-α pathway; this result in the inhibition of 
protein synthesis and an alteration of the transcriptome with dereg- 
ulation of genes involved in energy metabolism (Millino et al., 2009). 
Conversely, in SMA-3 muscles, increased levels of P38 kinase and a 
different transcriptional program, close to that found under normal 
conditions, were detected (Millino et al., 2009). Indeed, SMA-1 muscles 
appeared diffusely atrophic, while in SMA-3 samples the coexistence of 
atrophic and hypertrophic fibers could be appreciated. This findings 
might reflect the activation of different transcriptional pathways fol- 
lowing down- or upregulation of TNF-α cascade in SMA-1 and SMA-3. 
Activation of inflammatory pathways in SMA was further confirmed 
by Kim and colleagues, who reported that SMN depletion by RNA in- 
terference was able to potentiate IL-1β-induced IκB kinase (IKK) acti- 
vation and the subsequent production of inflammatory mediators such 
as TNF-α and NO in the SMN-deficient microglia (Kim and Choi, 2017). 
Pro-inflammatory cytokines such as interleukin-1β (IL-1β) and TNF-α 
induce the NF-κB signaling pathway through the activation of TRAF6 
and IκB kinase (IKK). Following these results, the authors speculated 
that SMN might function as an inhibitor of the NF-κB inflammatory 
signaling pathway in microglial cells, and its deficiency might instead 
trigger its activation. 
As mentioned above, activation of inflammatory pathways within 
glial cells leads to a secondary motoneuronal damage via synaptic re- 
modeling, induction of apoptosis and deprivation of trophic support. 
However, neuronal damage further reinforces these cascade generating 
a vicious cycle between glial cells and neurons. Indeed, subtle changes 
in the spinal microenvironment, elicited by compromised neurons, may 
be enough to activate neighboring glial cells. Researchers have de- 
monstrated that motor neurons, stressed by trophic factor deprivation 
or by FAS ligation, respond by producing NO and superoxide (Estévez 
et al., 1998). This two substances can react with each other to form 
peroxynitrite, which can trigger reactive morphological changes and 
GFAP and inducible nitric oxide synthase (iNOS) expression in neigh- 
boring astrocytes (Cassina et al., 2002). Similarly, microglial cells can 
be activated in vitro by the supernatant from cultured MN-like clonal 
cell lines deprived of trophic support (He et al., 2002). Thus, inter- 
vening in these cycle by blocking the inflammatory cascade might have 
huge beneficial effects at both a neuronal and glial level. 
 
6.4. Peripheral glial cells involvement in SMA 
 
As mentioned above, Schwann cells are the principal glial cells of 
the peripheral nervous system (PNS). There are two types of Schwann 
cells, myelinating and non-myelinating; myelinating ones are re- 
sponsible for the formation of the myelin sheath at the level of the 
motor and sensory neurons of the PNS (Chernousov et al., 2008). 
It has been recently reported that low levels of SMN in Schwann 
cells are able to trigger changes leading to abnormal axonal myelination 
and to the interruption of the deposition of extracellular matrix (ECM) 
proteins in peripheral nerves (Hunter et al., 2014) (Table 3). In one 
study, Hunter and colleagues showed that Schwann cells isolated from 
SMA mice have reduced levels of SMN and don't respond to normal 
differentiation signals in vitro (Hunter et al., 2014). Moreover, they 
were not able to correctly myelinate healthy neurons in co-cultures, and 
exerted a damaging influence on neural stability. An activation of the 
apoptotic cascade within the cells was also detected. These effects did 
not seem to be related to intrinsic neuronal defects, but rather were 
likely due to Schwann cell-dependent defects in the ECM of nerves. The 
selective genetic correction of SMN levels in Schwann cells reverted 
myelination    defects,    improved    neuromuscular    function    and 
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ameliorated neuromuscular junction pathology in SMA mice (Hunter 
et  al.,  2016). 
These findings thereby suggest that SMN deficiency might induce 
primary, intrinsic changes in Schwann cells, with consequences for 
myelination, axo–glial interactions and development of the ECM in the 
peripheral nerve. 
Schwann cells' defects appear to be able to induce pathology also at 
the level of the NMJ. A depletion of s100-positive perisynaptic Schwann 
cells was observed at that level of the NMJs in SMA mice (Neve et al., 
2016). Murray and colleagues identified a reduction in NMJ remodeling 
in SMA animal models and a loss of terminal Schwann cells which could 
contribute to this defect (Murray et al., 2013). 
Further studies have shown that Schwann cells in SMA models 
present different alterations at the level of growth pathways, cell death, 
survival and molecular transport. In particular, the ubiquitination 
pathways appeared to be disrupted in the Schwann cells lacking SMN 
(Aghamaleky Sarvestany et al., 2014). Furthermore, pharmacological 
suppression of an activator of the ubiquitin pathway in Schwann cells 
was sufficient to reproduce the defective myelination phenotype seen in 
SMA. Overall, these data highlight the important role of SMN in reg- 
ulating the ubiquitination pathway and in maintaining Schwann cell 
homeostasis. 
 
6.5. Oligodendrocytes involvement in SMA 
 
The role of oligodendrocytes in the pathogenesis of Spinal Muscular 
Atrophy was traditionally believed to be scarce. In 2017, a study con- 
ducted on a transgenic SMA mice did not reveal differences in oligo- 
dendrocytes differentiation, morphology and myelinating properties 
compared to control (O'Meara et al., 2017). However, a recent report by 
Ohuchi and colleagues has challenged this view, describing defects in 
the differentiation and function of cells of the oligodendrocytic lineage 
derived from SMA mice and from SMA-patients iPSCs (Ohuchi et al., 
2019a). In particular, expression of early (NG2) and late (MBP) markers 
of oligodendrocytes was reduced. Notch was involved in the decline of 
NG2 expression in the spinal cord of affected mice and, in addition, 
pharmacological Notch inhibition promoted differentiation of MBP- 
positive cells. Notably, oligodendrocytes' dysfunction appeared before 
motor neurons loss. 
Further studies are needed in order to elucidate the potential role of 
oligodendrocytes in SMA pathogenesis. Nevertheless, the involvement 
of the oligodendrocytic lineage does not appear unlikely at the light of 
the numerous observations of a glial cells alteration in SMA. 
 
7. Conclusions and future perspectives 
 
From all the studies discussed so far, it emerges that SMA is a non- 
cell autonomous disease in which glial cells and motor neurons influ- 
ence each other and contribute to denervation, synaptic loss and 
eventually cell death. Microglial cells and astroglial cell involvement 
has been widely investigated and is now increasingly recognized, while 
the role of peripheral Schwann cells is somewhat less delineated. 
Recently, a contribution of oligodendrocytes and of oligodendrocytes 
precursors has been revealed. 
Several mechanisms seem to be implicated in this glial-mediated 
damage, and many are probably still obscure. Nonetheless, from our 
discussion it emerges as a prominent culprit the disruption in different 
neuronal-glial interactions, such as synapse formation and remodeling, 
intercellular transmission and myelination. Moreover, a relevant role is 
also played by the neuroinflammatory pathways, with production of 
pro-inflammatory cytokines, induction of apoptotic cascade both in 
neurons and glial cells and generation of a neurotoxic milieu with 
spreading of neurodegeneration. Novel clues may also arise from evi- 
dence concerning the role of peripheral adaptive immunity in the reg- 
ulation of neuroinflammation in other neurodegenerative diseases, such 
as PD. T-lymphocytes were retrieved in psot-mortem brain specimens of 
animal models and PD patients (Brochard et al., 2009; McGeer et al., 
1988), and an alteration in the circulating T-lymphocytes profile with a 
shift towards a “pro-inflammatory” Th1 pattern was detected 
(Kustrimovic et al., 2018). Surprisingly, this field is still relatively un- 
explored in SMA, although a recent study detected thymic architecture 
abnormalities, aberrant T-cell development and global cytokine dysre- 
gulation in SMA mice (Deguise et al., 2017). Thus, a role of adaptive 
immune system in SMA pathogenesis can be hypothesized and warrants 
further studies. 
A deeper characterization of these processes in SMA is warranted, 
not only for a better understanding of the pathogenic mechanisms, but 
also for a refinement of our therapeutic weapons. In the last years, two 
novel therapies for SMA have been approved: nusinersen, an antisense 
oligonucleotide which favors the skipping of exon 7 of SMN2 mRNA, 
thus determining the production of a functional protein, and ona- 
semnogene abeparvovec, a gene therapy with AAV9 carrier which de- 
livers an exogenous SMN cDNA copy. Furthermore, other therapies are 
currently being tested, such as risdiplam, an orally-delivered, splicing 
modifier small-molecule (Poirier et al., 2018). In this perspective, the 
contribution of glial cells to SMA raises some questions. First, the ob- 
servation that glial cells dysfunction precedes motoneuronal loss in vivo 
should be taken into consideration for the definition of a therapeutic 
time window. Indeed, it could support the introduction of extensive 
newborn screening for SMN1 exon 7 deletion, in order to target SMN 
deficiency in childhood- or adult-onset forms before it becomes clini- 
cally evident. Additionally, it is evident from the studies discussed 
above that restoration of SMN expression both in motor neurons and in 
astrocytes is necessary in order to exert the maximal effect on survival. 
However, data regarding penetration of the aforementioned therapies 
in glial cells are not yet available. Notably, experimental data regarding 
adeno-associated vectors showed that AAV9 proved able to pre- 
ferentially transfect neurons in newborn mice and astrocytes in adult 
animals (Foust et al., 2009; Markakis et al., 2010). A further issue is 
represented by the involvement of peripheral nervous system, as several 
studies demonstrated an involvement of peripheral nerves, Schwann 
cells and neuromuscular junctions. Intrathecally-delivered therapies, 
such as nusinersen and other ASOs in general, are not able to reach this 
compartment, so it is possible that, with increasing use of this drug, we 
may witness the rise of new phenotypes dominated by peripheral and 
systemic symptoms. Surely, since it is now recognized that SMA is a 
multisystemic disease, rather than a motoneuronal one, the ideal dis- 
ease-modifying drug should have the potential to target both the central 
(neurons/glial cells) and peripheral (axons/Schwann cells/peripheral 
organs) compartments. On the hand, each cell type may require dif- 
ferent levels of SMN to function properly, thus the investigation of SMN 
levels regulation within different tissues and systems during develop- 
ment is warranted. The clarification of differential SMN expression 
during development and in different organs is important for the opti- 
mization of therapies not only for SMA-1 patients, but also for milder 
SMA forms, which seem to respond less optimally to CNS-directed SMN- 
restorative strategies, in part because the treatment is started later. 
Another interesting issue, as mentioned above, is the  potential in- 
volvement of adaptive immune system, which, if confirmed, could pave 
the way for preclinical and clinical trials with immunomodulatory 
drugs. 
Indeed, unraveling the molecular pathways that are affected by 
SMN deficiency also after the developmental phase, such as in- 
flammatory pathways, glial-mediated immune activation and synaptic 
remodeling, may shed a light on the mechanisms of neurodegeneration 
in adult life and pave the way for novel therapeutic strategies. 
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